vs
NATIONAL RESEARCH CORP（NRC）与OmniAb, Inc.（OABI）财务数据对比。点击上方公司名可切换其他公司
NATIONAL RESEARCH CORP的季度营收约是OmniAb, Inc.的4.2倍（$35.2M vs $8.4M）。NATIONAL RESEARCH CORP净利率更高（5.1% vs -169.3%，领先174.4%）。NATIONAL RESEARCH CORP同比增速更快（-4.6% vs -22.5%）。NATIONAL RESEARCH CORP自由现金流更多（$6.1M vs $-5.7M）。过去两年OmniAb, Inc.的营收复合增速更高（48.4% vs -0.2%）
NRC Health（原国家研究公司）是一家美国医疗健康企业，1981年成立，总部位于内布拉斯加州林肯市。公司主要在美加两国提供医疗健康相关产品及订阅式解决方案，深耕区域医疗健康服务领域。
OmniAb, Inc.是一家跨国生物技术企业，拥有专利转基因动物平台及全流程抗体发现解决方案，与全球制药和生物科技公司合作，加速肿瘤、自身免疫病等刚需医疗领域的全人源治疗抗体开发。
NRC vs OABI — 直观对比
营收规模更大
NRC
是对方的4.2倍
$8.4M
营收增速更快
NRC
高出17.8%
-22.5%
净利率更高
NRC
高出174.4%
-169.3%
自由现金流更多
NRC
多$11.7M
$-5.7M
两年增速更快
OABI
近两年复合增速
-0.2%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $35.2M | $8.4M |
| 净利润 | $1.8M | $-14.2M |
| 毛利率 | — | — |
| 营业利润率 | 13.3% | -188.2% |
| 净利率 | 5.1% | -169.3% |
| 营收同比 | -4.6% | -22.5% |
| 净利润同比 | -72.6% | -8.5% |
| 每股收益（稀释后） | $49.58 | $-0.11 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收NRCOABI
| Q4 25 | $35.2M | $8.4M | ||
| Q3 25 | $34.6M | $2.2M | ||
| Q2 25 | $34.0M | $3.9M | ||
| Q1 25 | $33.6M | $4.2M | ||
| Q4 24 | $36.9M | $10.8M | ||
| Q3 24 | $35.8M | $4.2M | ||
| Q2 24 | $35.0M | $7.6M | ||
| Q1 24 | $35.3M | $3.8M |
净利润NRCOABI
| Q4 25 | $1.8M | $-14.2M | ||
| Q3 25 | $4.1M | $-16.5M | ||
| Q2 25 | $-106.0K | $-15.9M | ||
| Q1 25 | $5.8M | $-18.2M | ||
| Q4 24 | $6.6M | $-13.1M | ||
| Q3 24 | $5.7M | $-16.4M | ||
| Q2 24 | $6.2M | $-13.6M | ||
| Q1 24 | $6.4M | $-19.0M |
营业利润率NRCOABI
| Q4 25 | 13.3% | -188.2% | ||
| Q3 25 | 22.4% | -810.2% | ||
| Q2 25 | 4.7% | -416.2% | ||
| Q1 25 | 25.6% | -453.6% | ||
| Q4 24 | 26.0% | -147.0% | ||
| Q3 24 | 22.3% | -473.7% | ||
| Q2 24 | 25.3% | -214.1% | ||
| Q1 24 | 24.8% | -593.3% |
净利率NRCOABI
| Q4 25 | 5.1% | -169.3% | ||
| Q3 25 | 11.9% | -738.1% | ||
| Q2 25 | -0.3% | -407.4% | ||
| Q1 25 | 17.2% | -438.1% | ||
| Q4 24 | 17.8% | -121.0% | ||
| Q3 24 | 15.9% | -392.4% | ||
| Q2 24 | 17.6% | -179.0% | ||
| Q1 24 | 18.0% | -498.8% |
每股收益（稀释后）NRCOABI
| Q4 25 | $49.58 | $-0.11 | ||
| Q3 25 | $0.18 | $-0.14 | ||
| Q2 25 | $-0.01 | $-0.15 | ||
| Q1 25 | $0.25 | $-0.17 | ||
| Q4 24 | $0.27 | $-0.13 | ||
| Q3 24 | $0.24 | $-0.16 | ||
| Q2 24 | $0.26 | $-0.13 | ||
| Q1 24 | $0.27 | $-0.19 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $4.1M | $25.5M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $14.0M | $267.0M |
| 总资产 | $134.9M | $300.9M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资NRCOABI
| Q4 25 | $4.1M | $25.5M | ||
| Q3 25 | $2.2M | $28.5M | ||
| Q2 25 | $5.3M | $18.3M | ||
| Q1 25 | $2.5M | $10.9M | ||
| Q4 24 | $4.2M | $27.6M | ||
| Q3 24 | $3.5M | $27.2M | ||
| Q2 24 | $485.0K | $20.8M | ||
| Q1 24 | $1.7M | $19.1M |
总债务NRCOABI
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $48.7M | — | ||
| Q2 24 | $33.3M | — | ||
| Q1 24 | $35.2M | — |
股东权益NRCOABI
| Q4 25 | $14.0M | $267.0M | ||
| Q3 25 | $14.3M | $277.4M | ||
| Q2 25 | $21.3M | $262.1M | ||
| Q1 25 | $29.7M | $273.5M | ||
| Q4 24 | $31.3M | $287.6M | ||
| Q3 24 | $34.6M | $291.7M | ||
| Q2 24 | $40.2M | $294.2M | ||
| Q1 24 | $36.9M | $301.4M |
总资产NRCOABI
| Q4 25 | $134.9M | $300.9M | ||
| Q3 25 | $135.7M | $309.7M | ||
| Q2 25 | $141.4M | $295.7M | ||
| Q1 25 | $135.2M | $306.2M | ||
| Q4 24 | $132.5M | $325.6M | ||
| Q3 24 | $131.8M | $331.6M | ||
| Q2 24 | $119.1M | $337.3M | ||
| Q1 24 | $120.9M | $352.6M |
负债/权益比NRCOABI
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.41× | — | ||
| Q2 24 | 0.83× | — | ||
| Q1 24 | 0.95× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $7.2M | $-5.7M |
| 自由现金流经营现金流 - 资本支出 | $6.1M | $-5.7M |
| 自由现金流率自由现金流/营收 | 17.2% | -67.8% |
| 资本支出强度资本支出/营收 | 3.2% | 0.1% |
| 现金转化率经营现金流/净利润 | 3.99× | — |
| 过去12个月自由现金流最近4个季度 | $15.7M | $-37.0M |
8季度趋势，按日历期对齐
经营现金流NRCOABI
| Q4 25 | $7.2M | $-5.7M | ||
| Q3 25 | $13.8M | $-9.8M | ||
| Q2 25 | $-1.1M | $-5.1M | ||
| Q1 25 | $6.6M | $-15.9M | ||
| Q4 24 | $6.4M | $-3.9M | ||
| Q3 24 | $9.4M | $-6.6M | ||
| Q2 24 | $6.8M | $-12.2M | ||
| Q1 24 | $12.0M | $-17.0M |
自由现金流NRCOABI
| Q4 25 | $6.1M | $-5.7M | ||
| Q3 25 | $10.2M | $-9.9M | ||
| Q2 25 | $-4.1M | $-5.3M | ||
| Q1 25 | $3.7M | $-16.1M | ||
| Q4 24 | $1.9M | $-3.9M | ||
| Q3 24 | $7.8M | $-6.7M | ||
| Q2 24 | $1.5M | $-12.9M | ||
| Q1 24 | $7.9M | $-18.0M |
自由现金流率NRCOABI
| Q4 25 | 17.2% | -67.8% | ||
| Q3 25 | 29.4% | -444.2% | ||
| Q2 25 | -12.2% | -136.3% | ||
| Q1 25 | 10.9% | -387.1% | ||
| Q4 24 | 5.2% | -36.3% | ||
| Q3 24 | 21.8% | -161.3% | ||
| Q2 24 | 4.3% | -169.9% | ||
| Q1 24 | 22.4% | -472.5% |
资本支出强度NRCOABI
| Q4 25 | 3.2% | 0.1% | ||
| Q3 25 | 10.4% | 8.1% | ||
| Q2 25 | 8.8% | 4.2% | ||
| Q1 25 | 8.9% | 5.0% | ||
| Q4 24 | 12.0% | 0.4% | ||
| Q3 24 | 4.5% | 3.6% | ||
| Q2 24 | 15.0% | 9.9% | ||
| Q1 24 | 11.7% | 24.4% |
现金转化率NRCOABI
| Q4 25 | 3.99× | — | ||
| Q3 25 | 3.34× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 1.15× | — | ||
| Q4 24 | 0.97× | — | ||
| Q3 24 | 1.66× | — | ||
| Q2 24 | 1.10× | — | ||
| Q1 24 | 1.89× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
